Research Progress in Blastic Plasmacytoid Dendritic Cell Neoplasm.
10.3881/j.issn.1000-503X.15946
- Author:
Fu-Yi LUO
1
;
Yan LI
2
Author Information
1. Graduate School,Hebei North University,Zhangjiakou,Hebei 075132,China.
2. Department of Hematology,Hebei General Hospital,Shijiazhuang 050051,China.
- Publication Type:Review
- Keywords:
blastic plasmacytoid dendritic cell neoplasm;
diagnosis;
treatment
- MeSH:
Humans;
Dendritic Cells;
Prognosis;
Diagnosis, Differential;
Immunophenotyping;
Skin Neoplasms/diagnosis*;
Hematologic Neoplasms/pathology*
- From:
Acta Academiae Medicinae Sinicae
2024;46(6):949-957
- CountryChina
- Language:English
-
Abstract:
Blastic plasmacytoid dendritic cell neoplasm(BPDCN)is an extremely rare invasive tumor with poor prognosis.The common clinical manifestations of BPDCN include skin injury,bone marrow involvement,and tumor cell spread.BPDCN is often misdiagnosed as other diseases and its diagnosis often requires a combination of clinical manifestations,imaging,histology,and immunophenotyping.Among them,immunophenotyping is crucial for the diagnosis of BPDCN.Although BPDCN is rare and no consensus has been reached on first-line treatment option,new drugs and options for treating this disease have emerged with the development of new drugs and increased awareness of BPDCN.This article reviews the research background,the origin of blastic plasmacytoid dendritic cells,and the recent research progress in the pathogenesis,diagnosis and differential diagnosis,treatment,and prognosis of BPDCN.
